Index

Note: Page numbers of article titles are in boldface type.

A
Abscess, dental infections as cause of brain, 574–577
waiting for development of before performing incision and drainage for deep neck infection, 513–518
clinical examinations, 515–516
diagnostic imaging, 516–517
historical views, 515
pathophysiology, 514–515
Actinomycosis, of the jaws, treatment of, 565–566
Allogeneic stem cell transplantation, oral infections in patients receiving, 579–599
bacterial, 585–586
fungal, 583–585
management of, 589–592
prevention of, 586–589
viral, 580–583
Antibacterial agents. See also Antibiotics.
for oral infections during, in patients undergoing allogeneic stem cell transplantation, 592
Antibiotics, and frequency of surgical site infections after impacted third mandibular molar surgery, 541–546
critically appraised topic approach to, 541–542
discussion, 544–545
results of literature review, 542–544
route of, 544
timing of, 544
of choice for odontogenic infections, 519–536
cost of oral, 529, 531
discussion, 529–534
duration of therapy, 529, 530
in clinical trials, 522–523
in laboratory studies, 523, 529
methods for review of literature on, 519–522
prophylactic, effect on rate of implant failure, 547–550
discussion, 548–550
methods for literature review on, 547–548
results of literature review on, 548
prophylactic, for removal of erupted teeth, 537–539
in healthy patients, 537–538
in patients with medical risk factors, 538–539
consequences of extraction-induced bacteremia, 538–538
systemic conditions predisposing to postoperative infections, 538
resistance to, minimizing our contribution to, 551–555
Antifungal agents, for oral infections during, in patients undergoing allogeneic stem cell transplantation, 590–592
systemic, 590–592
topical, 590
Apical periodontitis, role in severe head and neck infections, 499–500
B
Bacteremia, extraction-induced, consequences of, 538–539
oral, in patients receiving allogeneic stem cell transplantation, 585
Bacterial infections, in patients receiving allogeneic stem cell transplantation and other immunocompromised patients, 585–586
endodontic, 585–586
nonodontogenic, 586
odontogenic, 585
periodontal, 586
Biofilms, minimizing our contribution to antibiotic resistance, 551–555
role in osteomyelitis of the jaws, 563–564
role in severe head and neck infections, 497–505
bisphosphonate-related osteonecrosis of the jaws, 502
caries and apical periodontitis, 499–500
current trends, 503
dental plaque, 499
odontogenic infections, 502
osteomyelitis, 502–503
periodontitis and peri-implantitis, 500–502
Bisphosphonate-related osteonecrosis, of the jaws, role in severe head and neck infections, 502
Brain abscess, dental infections as cause of, 574–577
C
Candidiasis, oral, in patients receiving allogeneic stem cell transplantation, 583–585
invasive, 585
Caries, role in severe head and neck infections, 499–500
Cavernous sinus thrombosis, dental infections as cause of, 570–573
Central nervous system infections, dental infections as a cause of, 568–578
Central (continued)

brain abscess, 574–577
cavernous sinus thrombosis, 570–573
Costs, of oral antibiotics for odontogenic infections, 529, 531
Cytomegalovirus, orofacial, in patients receiving allogeneic stem cell transplantation, 582–583

D

Death, patient, malpractice cases involving oral and maxillofacial infections, lessons from, 601–607
Deep neck infections, waiting for development of abscess before performing incision and drainage, 513–518
clinical examinations, 515–516
diagnostic imaging, 516–517
historical views, 515
pathophysiology, 514–515
Dental implants. See Implants.
Dental treatments, to prevent oral infections in patients undergoing allogeneic stem cell transplantation, 586–587
Dentistry, evidence-based. See Evidence-based dentistry.
Dentists, minimizing our contribution to antibiotic resistance, 551–555
Drainage, for treatment of deep neck infection, waiting for development of abscess before incision and, 513–518

E

Endodontic infections, in patients receiving allogeneic stem cell transplantation, 585–586
Enteroviruses, orofacial, in patients receiving allogeneic stem cell transplantation, 583
Epstein-Barr virus, orofacial, in patients receiving allogeneic stem cell transplantation, 581–582
Erupted teeth, use of prophylactic antibiotics for removal of, 537–539
in healthy patients, 537–538
in patients with medical risk factors, 538–539
consequences of extraction-induced bacteremia, 538–538
systemic conditions predisposing to postoperative infections, 538
Evidence-based dentistry, effect of oral infections on systemic morbidity and mortality, 491–496
evidence and standards of care, 493
oral and systemic disease, 493–495
perceived deficits of, 493
variations in care and conflicting trial outcomes, 492–493
Extraction, of teeth, immediate vs. delayed in presence of acute infection, 507–511

F

Fungal infections, in patients receiving allogeneic stem cell transplantation and other immunocompromised patients, 583–585
antifungal agents for treatment of, 590–592
systemic, 590–592
topical, 590
invasive, 585

H

Head and neck infections. See also Deep neck infections.
role of biofilms in severe, 497–505
bisphosphonate-related osteonecrosis of the jaws, 502
caries and apical periodontitis, 499–500
current trends, 503
dental plaque, 499
odontogenic infections, 502
osteomyelitis, 502–503
periodontitis and peri-implantitis, 500–502
Hematopoietic stem cell transplantation (HCT), oral infections in patients receiving, 579–599
bacterial, 585–586
fungal, 583–585
management of, 589–592
prevention of, 586–589
oral hygiene regimens, 587
pre-HCT dental treatment, 586–587
systemic prophylactic agents, 587–589
viral, 580–583
Herpes simplex virus, orofacial, in patients receiving allogeneic stem cell transplantation, 580
Human herpes virus 8, orofacial, in patients receiving allogeneic stem cell transplantation, 583
Human papillomaviruses, orofacial, in patients receiving allogeneic stem cell transplantation, 583

I

Imaging, role in early diagnosis of osteomyelitis of the jaws, 558–562
Immunocompromised patients, oral infections in, 579–599
bacterial, 585–586
fungal, 583–585
management of, 589–592
prevention of, 586–589
viral, 580–583
Impacted teeth, antibiotics and frequency of surgical site infections after third molar extraction, 541–546
Implants, effect of prophylactic antibiotics on failure rate, 547–550
discussion, 548–550
methods for literature review on, 547–548
results of literature review on, 548
Incision, for treatment of deep neck infection, waiting for development of abscess before, 513–518
Infections, oral and maxillofacial, 491–607
antibiotics of choice and duration of treatment for odontogenic, 519–536
cost of oral, 529, 531
discussion, 529–534
duration of therapy, 529, 530
in clinical trials, 522–523
in laboratory studies, 523, 529
methods for review of literature on, 519–522
antibiotics’ effect on frequency of surgical site infections after impacted third molar surgery, 541–546
critically appraised topic approach to, 541–542
discussion, 544–545
results of literature review on, 542–544
central nervous system infections caused by, 569–578
brain abscess, 574–577
cavernous sinus thrombosis, 570–573
dentists’ role in minimizing antibiotic resistance, 551–555
early diagnosis and treatment of osteomyelitis of jaws, 557–567
classification, 557–558
clinical findings, 558
etiology, 558
laboratory findings, 562–563
new paradigm for maxillomandibular, 566
radiologic considerations, 558–562
role of biofilms, 563–564
special infections, 565–566
treatment, 564–565
effect on systemic morbidity and mortality, 491–496
evidence and standards of care, 493
perceived deficits of evidence-based dentistry, 493
variations in care and conflicting trial outcomes, 492–493
immediate vs. delayed extraction of teeth in presence of acute, 507–511
in allogeneic stem cell transplantation and other immunocompromised patients, bacterial, 585–586
fungal, 583–585
management of, 589–592
prevention of, 586–589
viral, 580–583
prophylactic antibiotics for removal of erupted teeth, 537–539
in healthy patients, 537–538
in patients with medical risk factors, 538–539
prophylactic antibiotics’ effect on implant failure, 547–550
review of recent closed malpractice cases involving, 601–607
role of biofilms in severe, 497–505
bisphosphonate-related osteonecrosis of the jaws, 502
caries and apical periodontitis, 499–500
current trends, 503
 dental plaque, 499
odontogenic infections, 502
osteomyelitis, 502–503
periodontitis and peri-implantitis, 500–502
waiting for development of abscess before performing incision and drainage, 513–518
waiting for development of abscess before performing incision and drainage for deep neck infection, clinical examinations, 515–516
diagnostic imaging, 516–517
historical views, 515
pathophysiology, 514–515
Inflammation, evidence on effect of oral infection on systemic disease, 493–495
M
Malpractice cases, involving oral and maxillofacial infections, lessons from, 601–607
Maxillofacial infections. See Infections, oral and maxillofacial.
Morbidity, systemic, evidence for effect of oral infections on, 491–496
Mortality, evidence for effect of oral infections on, 491–496
N
Neck infections. See Deep neck infections and Head and neck infections.
Neutropenia, preventing oral infections during, in patients undergoing allogeneic stem cell transplantation, 589
Nocardiosis, of the jaws, treatment of, 566
Nucleoside analogues, for oral infections in patients receiving allogeneic stem cell transplantation, 589–590
O
Odontogenic infections, antibiotics of choice and duration of treatment for, 519–536
cost of oral, 529, 531
discussion, 529–534
duration of therapy, 529, 530
Index

Odontogenic (continued)
in clinical trials, 522–523
in laboratory studies, 523, 529
methods for review of literature on, 519–522
in patients receiving allogeneic stem cell transplantation, 585
minimizing our contribution to antibiotic resistance, 551–555
role in severe head and neck infections, 502
Oral hygiene regimens, to prevent oral infections in patients undergoing allogeneic stem cell transplantation, 587
Oral infections. See Infections, oral and maxillofacial.
Osteomyelitis, of jaws, early diagnosis and treatment of, 557–567
classification, 557–558
clinical findings, 558
etiology, 558
laboratory findings, 562–563
new paradigm for maxillomandibular, 566
radiologic considerations, 558–562
role of biofilms, 563–564
special infections, 565–566
treatment, 564–565
of the jaws, early diagnosis and treatment, 557–567
role in severe head and neck infections, 502–503
Osteonecrosis, bisphosphonate-related, of the jaws, role in severe head and neck infections, 502

P
Peri-implantitis, role in severe head and neck infections, 500–502
Periocoronitis, immediate vs. delayed extraction of teeth, 507–511
Periodontal infections, in patients receiving allogeneic stem cell transplantation, 586
Periodontitis, and peri-implantitis, role in severe head and neck infections, 500–502
apical, role in severe head and neck infections, 499–500
Plaque, dental, role in severe head and neck infections, 499
Postoperative infections. See also Infections. after removal of erupted teeth, systemic conditions predisposing to, 538
Prophylactic agents, systemic, to prevent oral infections in patients undergoing allogeneic stem cell transplantation, 587–589
Prophylactic antibiotics, effect on rate of implant failure, 547–550
discussion, 548–550
methods for literature review on, 547–548
results of literature review on, 548
use for removal of erupted teeth, 537–539
in healthy patients, 537–538
in patients with medical risk factors, 538–539
consequences of extraction-induced bacteremia, 538–538
systemic conditions predisposing to postoperative infections, 538
R
Resistance, antibiotic, minimizing our contribution to, 551–555
S
Standards of care, evidence and, 493
Surgical procedures, immediate vs. delayed extraction of teeth with acute infection, 491–496
waiting for development of abscess before performing incision and drainage of deep neck infections, 513–518
Surgical site infections. See also Infections.
antibiotics and frequency of after impacted mandibular third molar surgery, 541–546
Systemic disease, evidence on effect of oral infection on, 493–495
T
Third molar extraction, antibiotics and frequency of surgical site infections after impacted, 541–546
immediate vs. delayed, in presence of acute infection, 507–511
Tooth extraction, immediate vs. delayed in presence of acute infection, 507–511
use of prophylactic antibiotics for removal of erupted teeth, 537–539
Treatment course, of antibiotics, duration of for odontogenic infections, 519–536
V
Varicella zoster virus, orofacial, in patients receiving allogeneic stem cell transplantation, 580–581
Viral infections, in patients receiving allogeneic stem cell transplantation and other immunocompromised patients, 580–583
antiviral agents for treatment of, 589–590
nucleoside analogues, 589–590
other, 590
cytomegalovirus, 582–583
enteroviruses, 583
Epstein-Barr virus, 581–582
herpes simplex virus, 580
human herpesvirus 8, 583
human papillomaviruses, 583
varicella zoster virus, 580–581